Diabetes (type 1 and type 2) in children and young people: diagnosis and management

In December 2025, we reviewed the recommendations on the effectiveness of glucose-lowering agents for type 2 diabetes in children and young people.

Surveillance decision

We will not update the recommendations as only one of the new randomised controlled trials identified in this review, evaluated a treatment that is licensed for use in children and young people (dapagliflozin), and there is no current intelligence that new treatments will be licensed in the near future. NICE should consider monitoring the licensing status and ongoing trials of new treatments before making a decision to update the guideline.